Publication:
Emerging Pharmacological Therapies for the Irritable Bowel Syndrome

dc.contributor.authorMonthira Maneerattanapornen_US
dc.contributor.authorLin Changen_US
dc.contributor.authorWilliam D. Cheyen_US
dc.contributor.otherUniversity of Michigan Health Systemen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherCURE: Digestive Disease Research Centeren_US
dc.contributor.otherUniversity of California, Los Angelesen_US
dc.date.accessioned2018-05-03T08:35:16Z
dc.date.available2018-05-03T08:35:16Z
dc.date.issued2011-03-01en_US
dc.description.abstractThe irritable bowel syndrome (IBS) is a symptom-based disorder defined by the presence of abdominal pain and altered bowel habits. Clinical presentations of IBS are diverse, with some patients reporting diarrhea, some constipation, and others a mixture of both. Like the varied clinical phenotypes, the pathogenesis of IBS is also diverse. IBS is not a single disease entity, but rather likely consists of several different disease states. This fact has important implications for the choices and efficacy of IBS treatment. This article reviews the IBS drugs that have reached phase II or III clinical trials. © 2011 Elsevier Inc.en_US
dc.identifier.citationGastroenterology Clinics of North America. Vol.40, No.1 (2011), 223-243en_US
dc.identifier.doi10.1016/j.gtc.2010.12.002en_US
dc.identifier.issn08898553en_US
dc.identifier.other2-s2.0-79951563809en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/12624
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79951563809&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleEmerging Pharmacological Therapies for the Irritable Bowel Syndromeen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79951563809&origin=inwarden_US

Files

Collections